File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Null mutations at the p66 and bradykinin 2 receptor loci induce divergent phenotypes in the diabetic kidney

TitleNull mutations at the p66 and bradykinin 2 receptor loci induce divergent phenotypes in the diabetic kidney
Authors
Issue Date2012
Citation
American Journal of Physiology - Renal Physiology, 2012, v. 303 n. 12, p. F1629-F1640 How to Cite?
AbstractCandidate genes have been identified that confer increased risk for diabetic glomerulosclerosis (DG). Mice heterozygous for the Akita (Ins2+/C96Y) diabetogenic mutation with a second mutation introduced at the bradykinin 2 receptor (B2R-/-) locus express a disease phenotype that approximates human DG. Src homology 2 domain transforming protein 1 (p66) controls mitochondrial metabolism and cellular responses to oxidative stress, aging, and apoptosis. We generated p66-null Akita mice to test whether inactivating mutations at the p66 locus will rescue kidneys of Akita mice from disease-causing mutations at the Ins2 and B2R loci. Here we show null mutations at the p66 and B2R loci interact with the Akita (Ins2+/C96Y) mutation, independently and in combination, inducing divergent phenotypes in the kidney. The B2R-/- mutation induces detrimental phenotypes, as judged by increased systemic and renal levels of oxidative stress, histology, and urine albumin excretion, whereas the p66-null mutation confers a powerful protection phenotype. To elucidate the mechanism(s) of the protection phenotype, we turned to our in vitro system. Experiments with cultured podocytes revealed previously unrecognized cross talk between p66 and the redox-sensitive transcription factor p53 that controls hyperglycemia-induced ROS metabolism, transcription of p53 target genes (angiotensinogen, angiotensin II type-1 receptor, and bax), angiotensin II generation, and apoptosis. RNA-interference targeting p66 inhibits all of the above. Finally, protein levels of p53 target genes were upregulated in kidneys of Akita mice but unchanged in p66-null Akita mice. Taken together, p66 is a potential molecular target for therapeutic intervention in DG. © 2012 the American Physiological Society.
Persistent Identifierhttp://hdl.handle.net/10722/195397
ISSN
2008 Impact Factor: 3.89
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorVashistha, H-
dc.contributor.authorSinghal, PC-
dc.contributor.authorMalhotra, A-
dc.contributor.authorHusain, M-
dc.contributor.authorMathieson, P-
dc.contributor.authorSaleem, MA-
dc.contributor.authorKuriakose, C-
dc.contributor.authorSeshan, S-
dc.contributor.authorWilk, A-
dc.contributor.authorDelValle, L-
dc.contributor.authorPeruzzi, F-
dc.contributor.authorGiorgio, M-
dc.contributor.authorPelicci, PG-
dc.contributor.authorSmithies, O-
dc.contributor.authorKim, H-S-
dc.contributor.authorKakoki, M-
dc.contributor.authorReiss, K-
dc.contributor.authorMeggs, LG-
dc.date.accessioned2014-02-28T06:12:05Z-
dc.date.available2014-02-28T06:12:05Z-
dc.date.issued2012-
dc.identifier.citationAmerican Journal of Physiology - Renal Physiology, 2012, v. 303 n. 12, p. F1629-F1640-
dc.identifier.issn0363-6127-
dc.identifier.urihttp://hdl.handle.net/10722/195397-
dc.description.abstractCandidate genes have been identified that confer increased risk for diabetic glomerulosclerosis (DG). Mice heterozygous for the Akita (Ins2+/C96Y) diabetogenic mutation with a second mutation introduced at the bradykinin 2 receptor (B2R-/-) locus express a disease phenotype that approximates human DG. Src homology 2 domain transforming protein 1 (p66) controls mitochondrial metabolism and cellular responses to oxidative stress, aging, and apoptosis. We generated p66-null Akita mice to test whether inactivating mutations at the p66 locus will rescue kidneys of Akita mice from disease-causing mutations at the Ins2 and B2R loci. Here we show null mutations at the p66 and B2R loci interact with the Akita (Ins2+/C96Y) mutation, independently and in combination, inducing divergent phenotypes in the kidney. The B2R-/- mutation induces detrimental phenotypes, as judged by increased systemic and renal levels of oxidative stress, histology, and urine albumin excretion, whereas the p66-null mutation confers a powerful protection phenotype. To elucidate the mechanism(s) of the protection phenotype, we turned to our in vitro system. Experiments with cultured podocytes revealed previously unrecognized cross talk between p66 and the redox-sensitive transcription factor p53 that controls hyperglycemia-induced ROS metabolism, transcription of p53 target genes (angiotensinogen, angiotensin II type-1 receptor, and bax), angiotensin II generation, and apoptosis. RNA-interference targeting p66 inhibits all of the above. Finally, protein levels of p53 target genes were upregulated in kidneys of Akita mice but unchanged in p66-null Akita mice. Taken together, p66 is a potential molecular target for therapeutic intervention in DG. © 2012 the American Physiological Society.-
dc.languageeng-
dc.relation.ispartofAmerican Journal of Physiology - Renal Physiology-
dc.titleNull mutations at the p66 and bradykinin 2 receptor loci induce divergent phenotypes in the diabetic kidney-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1152/ajprenal.00246.2012-
dc.identifier.pmid23019230-
dc.identifier.scopuseid_2-s2.0-84871344007-
dc.identifier.volume303-
dc.identifier.issue12-
dc.identifier.spageF1629-
dc.identifier.epageF1640-
dc.identifier.isiWOS:000312502100009-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats